In the April–June 2016 edition of Corporate Disputes, Dr. Gregory K. Bell discusses disputes in the healthcare and life sciences industry. In this roundtable discussion, the panel experts describe the underlying causes of recent disputes in the sector and highlight key cases. To read the article, click the link below.
Rebalancing resources for healthcare and medicines: How much is enough?
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.